PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026The Journal of Sexual Medicine0 citations

(022) Anorgasmia After Menopause

View Full Paper
RPR PopeAMA MyersJMJ Marino

Key Points

  • To explore the causes and treatment options for secondary anorgasmia and muted orgasm after menopause in women.
  • Chart review of patients at University Hospitals Cleveland Medical Center with secondary anorgasmia.
  • Exclusion of patients with primary anorgasmia.
  • Analysis of treatment effectiveness and patient outcomes.
  • 194 postmenopausal women identified with muted orgasm or anorgasmia.
  • Treatments included vaginal estrogen, compounded creams, and prasterone with varying success.
  • 30% of women reported achieving orgasm by their third visit, with prasterone and vibration showing the highest improvement.

Abstract

Abstract Introduction Postmenopausal anorgasmia is characterized by muted orgasm, delayed, orgasm, or inability to achieve orgasm. Typically it is distressing for women as they previously achieved satisfying orgasms. Etiology of postmenopausal orgasms is likely mulitifactorial and not yet clearly delineated as it could be a combination of blood flow, hormonal changes, and structural changes to the genitals. Objective To follow women seen in the female sexual medicine division for secondary muted orgasm or anorgasmia after menopause to understand etiology and treatment. Methods Charts were reviewed for any patient at University Hospitals Cleveland Medical Center for secondary anorgasmia or muted orgasm after menopause. Patients with primary anorgasmia were excluded. Results 194 women were found to have either muted orgasm or anorgasmia after menopause. Etiologies were unclear but likely multifactorial. Approximately 70% (n = 134) of them were started on vaginal estrogen, 20% (n = 39) were started on vaginal and estrogen compounded cream to be applied to the vestibule and/or clitoris, and 10% (n = 19) were started on vaginal prasterone. Approximately 30% (n = 58) were referred to behavioral health. 31% (n = 60) started on systemic testosterone. The average number of visits was three. 30% (n = 59) were able to achieve orgasm by this visit. Treatments most highly associated with successful orgasm/improvement of orgasm assessed by the patient’s report were prasterone and vibration. Conclusions More research is needed to understand the mechanism if action of anorgasmia after menopause to prevent it and treat it more quickly. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Astellas, Johnson & Johnson Global Public Health.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pope et al. (2026) studied this question.

synapsesocial.com/papers/69d896a46c1944d70ce082e1https://doi.org/10.1093/jsxmed/qdag063.022
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1(165) How Perimenopausal and Menopausal Women Perceive and Experience Sexual Arousal: Results of a Large, National Survey of 2,935 Perimenopausal and Menopausal U.S. Women2026
  2. 2(589) Clitoral Regeneration and Orgasmic Recovery after PRP + Hyaluronic Acid and Topical Testosterone in a Postmenopausal Woman: A Novel Multimodal Approach2026
  3. 3Sexual function in women with genitourinary menopausal syndrome2025
  4. 4(096) Promoting Menopausal Sexual Health Through an Education Module; A Pilot Study2026
  5. 5Recommendations for the management of postmenopausal vaginal atrophy2010 · 529 citations